How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,900 results for

Benign Prostatic Hyperplasia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

241. Comparison of Silodosin versus Tadalafil in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia. Full Text available with Trip Pro

Comparison of Silodosin versus Tadalafil in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia. To compare the efficacy and safety of silodosin versus tadalafil for treating lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH).After informed consent, patients with LUTS/BPH were randomized in a 1:1 ratio to receive silodosin 8 mg/day or tadalafil 5 mg/day for 8 weeks (Period 1). Patients treated with tadalafil entered (...) an exploratory phase and received silodosin or tadalafil for another 8 weeks. The primary efficacy endpoint was the change in the total International Prostate Symptom Score (IPSS) with Period 1 treatment.Both silodosin and tadalafil demonstrated statistically significant improvement in IPSS total symptom score, with a mean ± standard deviation change of -10.1 ± 6.4 (P < 0.0001) and -8.0 ± 6.3 (P < 0.0001), respectively. The former reduction was significantly greater than the latter (P = 0.0277). Adverse drug

2018 Lower urinary tract symptoms Controlled trial quality: uncertain

242. Re: Efficacy and Safety of Tadalafil 5mg Once Daily in the Treatment of Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia in Men Aged ≥75 years: Integrated Analyses of Pooled Data from Multinational, Randomized, Placebo-controlle (Abstract)

Re: Efficacy and Safety of Tadalafil 5mg Once Daily in the Treatment of Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia in Men Aged ≥75 years: Integrated Analyses of Pooled Data from Multinational, Randomized, Placebo-controlle 28162817 2018 04 30 2018 12 02 1873-7560 71 6 2017 06 European urology Eur. Urol. Re: Efficacy and Safety of Tadalafil 5mg Once Daily in the Treatment of Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia in Men Aged ≥75 (...) Carbolines Double-Blind Method Humans Lower Urinary Tract Symptoms Male Phosphodiesterase 5 Inhibitors Prostatic Hyperplasia Tadalafil Treatment Outcome 2017 01 09 2017 01 13 2017 2 7 6 0 2018 5 1 6 0 2017 2 7 6 0 ppublish 28162817 S0302-2838(17)30045-3 10.1016/j.eururo.2017.01.027

2018 European Urology Controlled trial quality: uncertain

243. Evaluation of the Therapeutic Effect against Benign Prostatic Hyperplasia and the Active Constituents from Epilobium angustifolium L. (Abstract)

Evaluation of the Therapeutic Effect against Benign Prostatic Hyperplasia and the Active Constituents from Epilobium angustifolium L. Plants of Epilobium angustifolium are popular in China to treatment of traumatic injury, subduing inflammation and menstrual disorders. In European, the preparations or extracts containing E. angustifolium are popular to treat prostate diseases. Recent research suggested that E. angustifolium showed therapeutic effects in early stage of BPH, inflammation (...) of urethra and prostate, as well as micturition problems. And the related researches were focus on aqueous extract and its main constituent of oenothein B.This study aims to evaluate the therapeutic effect against BPH of the ethyl acetate extracts (EAE) and n-butanol extracts (BUE) from E. angustifolium and to chemical investigation of the active constituents.The in vitro anti-BPH activity was assessed by determining the benign prostatic hyperplasia epithelial-1 (BPH-1) cell viability using MTT assay

2018 Journal of Ethnopharmacology

244. Alfuzosin in monotherapy and in combination therapy for the treatment of benign prostatic hyperplasia (BPH): efficacy and treatment profile

Alfuzosin in monotherapy and in combination therapy for the treatment of benign prostatic hyperplasia (BPH): efficacy and treatment profile Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2020 PROSPERO

245. Specific expression pattern of tissue cytokines analyzed through the Surface Acoustic Wave technique is associated with age-related spontaneous benign prostatic hyperplasia in rats Full Text available with Trip Pro

Specific expression pattern of tissue cytokines analyzed through the Surface Acoustic Wave technique is associated with age-related spontaneous benign prostatic hyperplasia in rats The aim of the study reported herein was to evaluate the suitability of the Surface Acoustic Wave (SAW) technique as a possible diagnostic tool in benign prostatic hyperplasia (BPH). Moreover, for the first time, the BPH model was a totally physiological using naturally aged rats with spontaneous, age-related BPH (...) instead of the pharmacologically induced models usually used. Eighteen male Wistar rats were distributed according to their age: 6 weeks (young), 12 weeks (adult) and 12 months (old) old. Prostate gland was removed and analyzed by mini-arrays, Western blotting (WB) and SAW techniques. Mini-arrays indicated that there were significant differences in the expression of 29/34 inflammation-related cytokines. WB was carried out to confirm the results after selection of 4 cytokines from which one showed

2018 Biochemistry and Biophysics Reports

246. Prescription pattern of alpha-blockers for management of lower urinary tract symptoms/benign prostatic hyperplasia Full Text available with Trip Pro

Prescription pattern of alpha-blockers for management of lower urinary tract symptoms/benign prostatic hyperplasia This study investigated trends in the prescription of α-blockers for patients with BPH, focusing on changing patterns of prescriptions during 2002-2013 using National Health Insurance Service-National Sample Cohort data. A total of 65,596 Korean males over 50 years old diagnosed with BPH were identified from the NHIS-NSC database between 2002-2013. Patterns of each α -blocker

2018 Scientific reports

247. Water vapor thermal therapy (WVTT) for lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH)

Water vapor thermal therapy (WVTT) for lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH) Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2020 PROSPERO

248. MECHANICAL AND ABLATIVE MINIMALLY INVASIVE TECHNIQUES FOR MALE LOWER URINARY TRACT SYMPTOMS DUE TO BENIGN PROSTATIC HYPERPLASIA: AN UPDATE OVERVIEW

MECHANICAL AND ABLATIVE MINIMALLY INVASIVE TECHNIQUES FOR MALE LOWER URINARY TRACT SYMPTOMS DUE TO BENIGN PROSTATIC HYPERPLASIA: AN UPDATE OVERVIEW Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2020 PROSPERO

249. The risks of delaying surgical procedures for benign prostatic hyperplasia or urinary stones due to the COVID-19 pandemic

The risks of delaying surgical procedures for benign prostatic hyperplasia or urinary stones due to the COVID-19 pandemic Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2020 PROSPERO

250. Comparative effectiveness of 3 urinating position for benign prostatic hyperplasia patient and health male:a bayesian network analysis

Comparative effectiveness of 3 urinating position for benign prostatic hyperplasia patient and health male:a bayesian network analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2020 PROSPERO

251. Components and incidence of the postembolization syndrome after transcatheter arterial embolization for the treatment of renal angiomyolipoma and benign prostatic hyperplasia: a systematic review

Components and incidence of the postembolization syndrome after transcatheter arterial embolization for the treatment of renal angiomyolipoma and benign prostatic hyperplasia: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2020 PROSPERO

252. Efficacy and safety of combination of tadalafil and tamsulosin for lower urinary tract symptoms secondary to benign prostatic hyperplasia and erectile dysfunction

Efficacy and safety of combination of tadalafil and tamsulosin for lower urinary tract symptoms secondary to benign prostatic hyperplasia and erectile dysfunction Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2020 PROSPERO

253. comparison of efficacy and side effects of minimally invasive treatments in benign prostatic hyperplasia

comparison of efficacy and side effects of minimally invasive treatments in benign prostatic hyperplasia Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2020 PROSPERO

254. Holmium Laser Technologies Versus Photoselective Greenlight Vaporization for Patients with Benign Prostatic Hyperplasia: A Meta-analysis

Holmium Laser Technologies Versus Photoselective Greenlight Vaporization for Patients with Benign Prostatic Hyperplasia: A Meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2020 PROSPERO

255. Effects of warm needling therapy on symptoms of benign prostatic hyperplasia: protocol for a systematic review and meta-analysis

Effects of warm needling therapy on symptoms of benign prostatic hyperplasia: protocol for a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2020 PROSPERO

256. Long-Term Clinical Efficacy and Safety Profile of Transurethral Resection of Prostate vs Plasmakinetic Resection of the Prostate for Benign Prostatic Hyperplasia. (Abstract)

Long-Term Clinical Efficacy and Safety Profile of Transurethral Resection of Prostate vs Plasmakinetic Resection of the Prostate for Benign Prostatic Hyperplasia. To investigate the differences on clinical efficacy, complications, and safety profile between transurethral resection of the prostate (TURP) and bipolar plasmakinetic resection of the prostate (PKRP) for benign prostatic hyperplasia (BPH).Six hundred ninety patients of BPH were recruited from May 2008 to May 2011 and divided (...) into TURP group and PKRP group. The International Prostate Symptom Score (IPSS), quality of life score (QoL), postvoid residual urine (PVR), maximum flow rate (Qmax), complications, International Index of Erectile Function-5 (IIEF-5) questionnaire, and retrograde ejaculation were used for evaluation of clinical efficacy and safety and sexual function between the 2 groups.The intraoperative irrigation volume, postoperative irrigation volume, postoperative irrigation time, decrease in sodium

2017 Urology

257. Alterations in expressed prostate secretion-urine PSA N-glycosylation discriminate prostate cancer from benign prostate hyperplasia Full Text available with Trip Pro

Alterations in expressed prostate secretion-urine PSA N-glycosylation discriminate prostate cancer from benign prostate hyperplasia The prostate specific antigen (PSA) test is widely used for early diagnosis of prostate cancer (PCa). However, its limited sensitivity has led to over-diagnosis and over-treatment of PCa. Glycosylation alteration is a common phenomenon in cancer development. Different PSA glycan subforms have been proposed as diagnostic markers to better differentiate PCa from (...) benign prostate hyperplasia (BPH). In this study, we purified PSA from expressed prostate secretions (EPS)-urine samples from 32 BPH and 30 PCa patients and provided detailed PSA glycan profiles in Chinese population. We found that most of the PSA glycans from EPS-urine were complex type biantennary glycans. We observed two major patterns in PSA glycan profiles. Overall there was no distinct separation of PSA glycan profiles between BPH and PCa patients. However, we detected a significant increase

2017 Oncotarget

258. Comparison of Visual Prostate Symptom Score and International Prostate Symptom Score in the evaluation of men with benign prostatic hyperplasia: A prospective study from an Indian population Full Text available with Trip Pro

Comparison of Visual Prostate Symptom Score and International Prostate Symptom Score in the evaluation of men with benign prostatic hyperplasia: A prospective study from an Indian population Lower urinary tract symptoms (LUTSs) due to benign prostatic hyperplasia (BPH) are common conditions in middle-age or older men. The International Prostate Symptom Score (IPSS) is a useful and validated questionnaire to evaluate LUTS secondary to BPH. Van der Walt et al have developed an alternative (...) questionnaire named the Visual Prostate Symptom Score (VPSS) questionnaire. This study aimed to evaluate the relationship between the VPSS and IPSS in the evaluation of men with LUTSs due to BPH in an Indian population.This was a prospectively designed study conducted at Sri Sathya Sai Institute of Higher Medical Sciences, Prashanthigram (Anantapur, Andhra Pradesh, India). A total of 121 patients who presented to the urology outpatient department with LUTS due to BPH were enrolled in the study. Patients

2017 Prostate international

259. [Laser treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia]

[Laser treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia] Traitement des symptômes du bas appareil urinaire liés à l'hypertrophie bénigne de la prostate par laser [Laser treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia] Traitement des symptômes du bas appareil urinaire liés à l'hypertrophie bénigne de la prostate par laser [Laser treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (...) ] Haute Autorité de Santé Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Haute Autorité de Santé. Traitement des symptômes du bas appareil urinaire liés à l'hypertrophie bénigne de la prostate par laser. [Laser treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia] Paris: Haute Autorité de Santé (HAS). 2013

2013 Health Technology Assessment (HTA) Database.

260. Management of Benign Prostatic Hyperplasia (BPH)

Management of Benign Prostatic Hyperplasia (BPH) Management of Benign Prostatic Hyperplasia - American Urological Association advertisement Toggle navigation About Us About the AUA Membership AUA Governance Industry Relations Education AUAUniversity Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Andrenal Gland Testis Paratesticular Tumors Penis Retroperitoneum Cytology Online Learning For Medical (...) ) Patient Safety and Quality of Care Accreditations and Reporting Patient Education Management of Benign Prostatic Hyperplasia Published 2010; Reviewed and Validity Confirmed 2014 Benign prostatic hyperplasia (BPH) is a histologic diagnosis that refers to the proliferation of smooth muscle and epithelial cells within the prostatic transition zone. This guideline discusses proper evaluation and management, including interventional therapy, and treatment alternatives. [pdf] Panel Members Kevin T. McVary

2014 American Urological Association

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>